Objectives: Proton pump inhibitors (PPIs) are frequently prescribed to patients with Barrett's esophagus (BE), but in a subset, they can induce significant hypergastrinemia. Elevated levels of gastrin have been associated with tumorigenic effects in a number of gastrointestinal cancers. We decided to investigate the association between serum gastrin levels and dysplasia in BE.
Methods: We performed a cross-sectional study and enrolled patients with BE without dysplasia, low-grade dysplasia (LGD), high-grade dysplasia (HGD), or adenocarcinoma (AC), as well as gastroesophageal reflux disease controls, all chronically taking PPIs. Fasting serum gastrin was measured, and data were collected on patient characteristics, medication use, and the highest degree of BE neoplasia.
Results: A total of 95 patients were enrolled. The mean age was 64.7 (+/-10.0) years, and 70.5% were male. The median serum gastrin level was 40 pM. There was no significant difference in gastrin levels with increased degrees of BE neoplasia (overall P=0.68). In multivariable analysis, the highest quartile of gastrin was associated with significantly increased odds of advanced neoplasia (HGD or AC) (odds ratio (OR): 5.46, 95% confidence interval (CI): 1.20-24.8).
Conclusions: In BE patients taking PPIs, an elevated serum gastrin is associated with a history of HGD or AC. Prospective studies are needed to determine whether patients with nondysplastic BE and elevated serum gastrin are at increased risk for neoplastic progression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139948 | PMC |
| http://dx.doi.org/10.1038/ajg.2009.629 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hp eradication decreased the expression level of PG II in patients of Hp negative with gastric intestinal metaplasia: a retrospective cross-sectional study.
J Health Popul Nutr
January 2025
Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical University, Huaihai West Road, Xuzhou, Jiang Su, 221004, China.
Aims: This study aims to assess the serum levels of pepsinogen (PG)I, PG II, and gastrin (G17) in patients with gastric intestinal metaplasia (GIM) and evaluate their correlation with demographic characteristics.
Methods: A total of 247 normal controls (NC) and 240 patients diagnosed with GIM were enrolled in this study. All participants underwent a gastroscopy procedure followed by pathological examination for diagnosis confirmation.
The Evaluation of Urinary HE4, CEA, ProGRP, CYFRA 21-1 and NSE in the Diagnosis of Lung Cancer.
Ann Clin Lab Sci
November 2024
Department of Clinical Laboratory Medicine, the First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Laboratory Medicine, Jinan, China
Objective: Urinary proteins are effective tumor biomarkers. Human epididymis protein 4 (HE4), progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), cytokeratin-19 fragment 21-1(CYFRA 21-1), and neuron-specific enolase (NSE) in serum, were proposed as tumor biomarkers of lung cancer. Our aim was to identify the urine protein biomarkers that can distinguish patients with lung cancer from healthy individuals and/or patients with benign lung disease with a high level of sensitivity and specificity.
View Article and Find Full Text PDFSerum levels of PSA and VEGF2 as the prognosis markers for bone metastasis of prostate cancer: A retrospective study.
Comput Biol Chem
December 2024
Department of Emergency, Wuhan No.6 Hospital(Affiliated Hospital of Jianghan University), No.168, Xianggang Road, Jiangan District, Wuhan, Hubei 430015, China. Electronic address:
Background And Objective: Prostate cancer (PCa) is the second most commonly diagnosed cancer in males, the mechanism of PCa with bone metastasis remains unclear. In this study, we aimed to utilize a retrospective clinical study to evaluate the diagnostic value of bone metastases from PCa and provide reference values for future applications.
Methods: We retrospectively collected a total of 200 samples including 100 PCa patients with bone metastatic and 100 without from June 2019 to August 2021.
A Pharmacokinetic/Pharmacodynamic Study of Esomeprazole Comparing a Dual Delayed-Release Formulation (YYD601) to a Conventional Formulation Following Multiple Administrations in Healthy Adult Subjects.
Drug Des Devel Ther
January 2025
School of Medicine, Kyungpook National University and Department of Clinical Pharmacology and Therapeutics, Kyungpook National University Hospital, Daegu, 41944, Republic of Korea.
Background: YYD601 is a new dual delayed-release formulation of esomeprazole, developed to enhance plasma exposure and prolong the duration of acid suppression.
Purpose: This study aimed to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of YYD601 20 mg following single and multiple oral administrations in healthy, fasting adult Koreans, and to compare these outcomes to those of the conventional esomeprazole 20 mg capsule.
Methods: A randomized, open-label, two-period crossover study was conducted in 28 participants, who were divided into two treatment groups: one group received YYD601 20 mg, and the other received conventional esomeprazole 20 mg, once daily for five consecutive days.
Atropine plus omeprazole for acute gastritis: Efficacy and safety analysis.
Pak J Pharm Sci
January 2025
Jian'ou Municipal Hospital, Nanping, Fujian, China.
Article Synopsis
- The article evaluates the effectiveness and safety of a combination treatment of atropine (ATR) and omeprazole (OME) for acute gastritis (AG) in comparison to anisodamine (ADM) with OME.
- The study involved 95 patients, with the ATR+OME group showing a higher success rate, fewer side effects, and quicker symptom relief than the ADM+OME group.
- Results indicated that the ATR+OME treatment significantly reduced inflammatory markers and gastrointestinal hormone levels, suggesting its strong efficacy and safety for managing AG, making it suitable for wider clinical use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!